European Commission approves Reblozyl for first-line anemia treatment in low, very low, and intermediate-risk myelodysplastic syndromes.

The European Commission has granted Bristol Myers Squibb the approval to expand the use of Reblozyl (luspatercept) for first-line treatment of adult patients with anemia due to very low, low and intermediate-risk myelodysplastic syndromes. The approval was based on data from the Phase 3 COMMANDS study, which showed superior efficacy for Reblozyl compared to epoetin alfa. Safety results were consistent with previous MDS studies.

April 03, 2024
3 Articles